digoxin and 2-(3-4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile

digoxin has been researched along with 2-(3-4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile* in 1 studies

Other Studies

1 other study(ies) available for digoxin and 2-(3-4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile

ArticleYear
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
    The Journal of pharmacology and experimental therapeutics, 2000, Volume: 293, Issue:2

    Verapamil is subject to extensive oxidative metabolism mediated by cytochrome P450 enzymes with less than 5% of an oral dose being excreted unchanged in urine. Furthermore, verapamil is known to be a potent inhibitor of P-glycoprotein function. There is evidence from in vivo investigations that some verapamil metabolites might be actively transported. The aim of the present study was to investigate P-glycoprotein-mediated transport and inhibition properties of verapamil and its metabolites norverapamil, D-620, D-617, and D-703. Polarized transport of these compounds was assessed in P-glycoprotein-expressing Caco-2 and L-MDR1 cells (LLC-PK1 cells stably transfected with human MDR1-P-glycoprotein). Inhibition of P-glycoprotein-mediated transport by these compounds was determined using digoxin as P-glycoprotein substrate. At concentrations of 5 microM, significant differences between basal-to-apical and apical-to-basal apparent permeability coefficients were observed for D-617 and D-620 in all P-glycoprotein-expressing cell monolayers, indicating that both are P-glycoprotein substrates. In contrast, no P-glycoprotein-dependent transport was found for verapamil, norverapamil, and D-703 in Caco-2 cells and for D-703 in L-MDR1 cells. Moreover, verapamil, norverapamil, and D-703 inhibited P-glycoprotein-mediated digoxin transport with IC(50) values of 1.1, 0.3, and 1.6 microM, respectively, whereas D-617 and D-620 did not (at concentrations up to 100 microM). We conclude that verapamil phase I metabolites exhibit different P-glycoprotein substrate and inhibition characteristics, with the N-dealkylated metabolites D-617 and D-620 being P-glycoprotein substrates and norverapamil and D-703 being inhibitors of P-glycoprotein function, which may influence P-glycoprotein-dependent drug disposition and elimination.

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Calcium Channel Blockers; Cardiotonic Agents; Cell Line; Digoxin; Epithelial Cells; Humans; Kinetics; LLC-PK1 Cells; Nitriles; Swine; Verapamil

2000